{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:39:24Z","timestamp":1792690764205,"version":"4.5.0"},"reference-count":185,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:23:38Z","timestamp":1741782218000},"page":"2065-2081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Progress in skin gene therapy: From the inside and out"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-0841","authenticated-orcid":false,"given":"Mark J.","family":"Osborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Reineke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.017_bib1","series-title":"Anatomy, Skin (Integument), Epidermis. In StatPearls","author":"Yousef","year":"2025"},{"key":"10.1016\/j.ymthe.2025.03.017_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/geno.1994.1239","article-title":"Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene","volume":"21","author":"Christiano","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.ymthe.2025.03.017_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jmg.2006.045302","article-title":"Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes","volume":"44","author":"Varki","year":"2007","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ymthe.2025.03.017_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bbrc.2006.03.034","article-title":"High-affinity binding of the NC1 domain of collagen VII to laminin 5 and collagen IV","volume":"343","author":"Brittingham","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.03.017_bib5","doi-asserted-by":"crossref","first-page":"14516","DOI":"10.1074\/jbc.272.23.14516","article-title":"Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin","volume":"272","author":"Chen","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.017_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2009.04363.x","article-title":"Making an epidermis","volume":"1170","author":"Koster","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.03.017_bib7","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20178174","article-title":"Fibroblast state switching orchestrates dermal maturation and wound healing","volume":"14","author":"Rognoni","year":"2018","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jid.2024.01.040","article-title":"Collagen VII\u2019s Dual Mesenchymal and Epithelial Origins: Implications for Molecular Corrective Therapies","volume":"145","author":"Bagci","year":"2025","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib9","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2353\/ajpath.2009.090347","article-title":"Keratinocyte-\/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation","volume":"175","author":"Ito","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1600-0625.2008.00723.x","article-title":"Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa","volume":"17","author":"Dang","year":"2008","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.03.017_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MOP.0b013e32833bb74f","article-title":"Inherited epidermolysis bullosa: recent basic and clinical advances","volume":"22","author":"Fine","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.ymthe.2025.03.017_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2340\/00015555-2781","article-title":"Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand","volume":"98","author":"Kim","year":"2018","journal-title":"Acta. Derm. Venereol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/mt.2015.58","article-title":"High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa","volume":"23","author":"K\u00fchl","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1523-1747.2003.12571.x","article-title":"Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone","volume":"121","author":"Woodley","year":"2003","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/mt.2009.144","article-title":"Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity","volume":"17","author":"Kern","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib17","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bjd.12599","article-title":"Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial","volume":"169","author":"Petrof","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","article-title":"A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Venugopal","year":"2013","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjd.16338","article-title":"Cultured allogeneic fibroblast injection vs. fibroblasts cultured on amniotic membrane scaffold for dystrophic epidermolysis bullosa treatment","volume":"179","author":"Moravvej","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fimmu.2020.00648","article-title":"Interplay Between Keratinocytes and Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin Fibrotic Disorders","volume":"11","author":"Russo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/JID.2015.364","article-title":"Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB","volume":"136","author":"Georgiadis","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jid.2016.02.811","article-title":"Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector","volume":"136","author":"Jack\u00f3w","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.017_bib25","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2025.03.017_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.017_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","article-title":"Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa","volume":"17","author":"So","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.03.017_bib28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/17425247.2023.2209719","article-title":"Iontophoresis for the cutaneous delivery of nanoentraped drugs","volume":"20","author":"Andrade","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2025.03.017_bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ymthe.2004.05.016","article-title":"Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in\u00a0vivo","volume":"10","author":"Woodley","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.virol.2018.07.011","article-title":"Strength in diversity: Understanding the pathways to herpes simplex virus reactivation","volume":"522","author":"Suzich","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.017_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-53168-7_6","article-title":"Herpesvirus Capsid Assembly and DNA Packaging","volume":"223","author":"Heming","year":"2017","journal-title":"Adv. Anat. Embryol. Cel Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/rmv.409","article-title":"Herpes simplex virus gene products: the accessories reflect her lifestyle well","volume":"14","author":"Nishiyama","year":"2004","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib34","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/sj.gt.3300766","article-title":"Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons","volume":"5","author":"Krisky","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib35","doi-asserted-by":"crossref","first-page":"E1632","DOI":"10.1073\/pnas.1423556112","article-title":"Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity","volume":"112","author":"Miyagawa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.017_bib36","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1128\/JVI.72.4.3307-3320.1998","article-title":"Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins","volume":"72","author":"Samaniego","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib37","first-page":"1","article-title":"Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update","author":"Le Hars","year":"2024","journal-title":"Gene. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In\u00a0vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib39","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N.\u00a0Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.ymthe.2025.03.017_bib40","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJMoa2301244","article-title":"Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa","volume":"390","author":"Tovar Vetencourt","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature16506","article-title":"A mechanism of viral immune evasion revealed by cryo-EM analysis of the TAP transporter","volume":"529","author":"Oldham","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/156652305774329285","article-title":"HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy","volume":"5","author":"Epstein","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-0428-0_5","article-title":"Engineering HSV-1 vectors for gene therapy","volume":"1144","author":"Goins","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-1-4939-2152-2_20","article-title":"Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy","volume":"1254","author":"Marconi","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib46","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.017_bib47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/jamadermatol.2023.5857","article-title":"Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa","volume":"160","author":"Raymakers","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib49","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jid.2016.11.038","article-title":"Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes","volume":"137","author":"Latella","year":"2017","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib50","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/mt.2010.91","article-title":"SIN retroviral vectors expressing COL7A1 under human promoters for ex\u00a0vivo gene therapy of recessive dystrophic epidermolysis bullosa","volume":"18","author":"Titeux","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib51","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jid.2016.05.115","article-title":"miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa","volume":"136","author":"Vanden Oever","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib52","doi-asserted-by":"crossref","first-page":"13053","DOI":"10.1074\/jbc.273.21.13053","article-title":"Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-beta","volume":"273","author":"Vindevoghel","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.017_bib53","first-page":"S29","article-title":"Tissue-specific downregulation of type VII collagen gene (COL7A1) transcription in cultured epidermal keratinocytes by ultraviolet A radiation (UVA) and UVA-inducibte cytokines, with special reference to cutaneous photoaging","volume":"1","author":"Kon","year":"2005","journal-title":"J.\u00a0Dermatol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.017_bib54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/mt.2016.199","article-title":"Gene Therapy for Epidermolysis Bullosa: Sticky Business","volume":"24","author":"Nystr\u00f6m","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1126\/science.2660260","article-title":"Altering the genome by homologous recombination","volume":"244","author":"Capecchi","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.017_bib56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0168-9525(96)10019-6","article-title":"Genetic manipulation of genomes with rare-cutting endonucleases","volume":"12","author":"Jasin","year":"1996","journal-title":"Trends Genet."},{"key":"10.1016\/j.ymthe.2025.03.017_bib57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1126\/science.1079512","article-title":"Enhancing gene targeting with designed zinc finger nucleases","volume":"300","author":"Bibikova","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.017_bib58","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.1078395","article-title":"Chimeric nucleases stimulate gene targeting in human cells","volume":"300","author":"Porteus","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.017_bib59","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/nar\/gkr218","article-title":"Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting","volume":"39","author":"Cermak","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.017_bib60","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based gene correction for epidermolysis bullosa","volume":"21","author":"Osborn","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-1862-1_7","article-title":"Efficient design and assembly of custom TALENs using the Golden Gate platform","volume":"1239","author":"Cermak","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib62","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 Editing via CRISPR\/Cas9 in Recessive Dystrophic Epidermolysis Bullosa","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib63","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.017_bib64","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.jid.2020.02.012","article-title":"Predictable CRISPR\/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa","volume":"140","author":"Kocher","year":"2020","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtn.2018.01.009","article-title":"Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells","volume":"11","author":"Menc\u00eda","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.017_bib66","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jid.2019.02.015","article-title":"Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR\/Cas9","volume":"139","author":"Takashima","year":"2019","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib67","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/labinvest.2017.85","article-title":"Rapid generation of Col7a1(-\/-) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells","volume":"97","author":"Webber","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ymthe.2025.03.017_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/npjregenmed.2016.14","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa","volume":"1","author":"Webber","year":"2016","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib69","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/nar\/gkaa1251","article-title":"Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing","volume":"49","author":"Fu","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.017_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/srep23549","article-title":"Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing","volume":"6","author":"Miyaoka","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.017_bib71","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.03.017_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib74","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2025.03.017_bib75","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","article-title":"On- and off-target effects of paired CRISPR-Cas nickase in primary human cells","volume":"32","author":"Klermund","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib76","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u22c5T to G\u22c5C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib77","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib78","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib79","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","article-title":"Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs","volume":"140","author":"Osborn","year":"2020","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib80","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","article-title":"Directed evolution of adenine base editors with increased activity and therapeutic application","volume":"38","author":"Gaudelli","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24184-8","article-title":"ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation","volume":"12","author":"Sheriff","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.017_bib83","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41587-023-01821-9","article-title":"Adenine transversion editors enable precise, efficient A\u22c5T-to-C\u22c5G base editing in mammalian cells and embryos","volume":"42","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib84","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41467-021-21559-9","article-title":"Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.017_bib85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41587-020-0609-x","article-title":"CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells","volume":"39","author":"Kurt","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib86","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41587-022-01595-6","article-title":"Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase","volume":"41","author":"Tong","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib87","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41587-023-02050-w","article-title":"Glycosylase-based base editors for efficient T-to-G and C-to-G editing in mammalian cells","volume":"42","author":"Ye","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41587-020-0592-2","article-title":"Glycosylase base editors enable C-to-A and C-to-G base changes","volume":"39","author":"Zhao","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib89","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.ymthe.2022.06.005","article-title":"Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa","volume":"30","author":"Hong","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib90","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cellule"},{"key":"10.1016\/j.ymthe.2025.03.017_bib91","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","article-title":"Improving prime editing with an endogenous small RNA-binding protein","volume":"628","author":"Yan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib92","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","volume":"9","author":"Pandey","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.03.017_bib95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41587-023-01748-1","article-title":"Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases","volume":"42","author":"Lampe","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib96","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.18632\/oncotarget.8340","article-title":"Nectin-1 and HVEM: cellular receptors for HSV-1 in skin","volume":"7","author":"Knebel-M\u00f6rsdorf","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.03.017_bib97","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1128\/JVI.01582-16","article-title":"Herpes Simplex Virus 1 Enters Human Keratinocytes by a Nectin-1-Dependent, Rapid Plasma Membrane Fusion Pathway That Functions at Low Temperature","volume":"90","author":"Sayers","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.644664","article-title":"Herpes Simplex Virus 1 Infection of Neuronal and Non-Neuronal Cells Elicits Specific Innate Immune Responses and Immune Evasion Mechanisms","volume":"12","author":"Verzosa","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib99","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-023-01921-5","article-title":"Beremagene Geperpavec: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.03.017_bib100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/bjd\/ljad433","article-title":"Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper","volume":"190","author":"Doolan","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib101","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ymthe.2020.02.010","article-title":"Did Dendritic Cell Activation, Induced by Adenovirus-Antibody Complexes, Play a Role in the Death of Jesse Gelsinger?","volume":"28","author":"Baker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib102","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib103","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/v15091801","article-title":"Innate Immune Response to Viral Vectors in Gene Therapy","volume":"15","author":"Wang","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.017_bib104","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","article-title":"Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities","volume":"17","author":"Karlsson","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2025.03.017_bib105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jconrel.2016.06.014","article-title":"Highly branched poly(\u03b2-amino ester)s for skin gene therapy","volume":"244","author":"Zhou","year":"2016","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2025.03.017_bib106","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600102","article-title":"The transition from linear to highly branched poly(\u03b2-amino ester)s: Branching matters for gene delivery","volume":"2","author":"Zhou","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.017_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113842","article-title":"Highly branched poly(\u03b2-amino ester)s for gene delivery in hereditary skin diseases","volume":"176","author":"Zeng","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.017_bib108","doi-asserted-by":"crossref","first-page":"30661","DOI":"10.1021\/acsami.9b13135","article-title":"Efficient and Robust Highly Branched Poly(\u03b2-amino ester)\/Minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes","volume":"11","author":"Zeng","year":"2019","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.ymthe.2025.03.017_bib109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.017_bib111","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2025.03.017_bib112","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2025.03.017_bib113","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.017_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902575","article-title":"Fast and Efficient CRISPR\/Cas9 Genome Editing In\u00a0Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2025.03.017_bib115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.ymthe.2025.03.017_bib116","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.017_bib117","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In\u00a0Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2025.03.017_bib118","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2022019333","article-title":"Lipid nanoparticles allow efficient and harmless ex\u00a0vivo gene editing of human hematopoietic cells","volume":"142","author":"Vavassori","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.017_bib119","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","article-title":"Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In\u00a0Vivo CRISPR\/Cas-Based Genome Editing","volume":"14","author":"Wei","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2025.03.017_bib120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.017_bib121","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/genbio.2023.0045","article-title":"In\u00a0Vivo Prime Editing by Lipid Nanoparticle Co-delivery of Chemically Modified pegRNA and Prime Editor mRNA","volume":"2","author":"Chen","year":"2023","journal-title":"GEN. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","article-title":"Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations","volume":"9","author":"Ho\u0142ubowicz","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.03.017_bib123","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.jid.2024.03.027","article-title":"Lipid Nanoparticles Efficiently Deliver the Base Editor ABE8e for COL7A1 Correction in Dystrophic Epidermolysis Bullosa Fibroblasts In\u00a0Vitro","volume":"144","author":"Guri-Lamce","year":"2024","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib124","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41551-022-00989-w","article-title":"Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy","volume":"7","author":"You","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.03.017_bib125","doi-asserted-by":"crossref","first-page":"22046","DOI":"10.1021\/acsnano.3c08644","article-title":"Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human Skin","volume":"17","author":"Bolsoni","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2025.03.017_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2888","article-title":"Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders","volume":"7","author":"Wan","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.017_bib127","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","author":"Woodley","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib129","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jid.2021.09.008","article-title":"Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa","volume":"142","author":"Gretzmeier","year":"2022","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib130","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","author":"Woodley","year":"2013","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib131","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1038\/jid.2015.291","article-title":"Intravenously Administered Recombinant Human Type VII Collagen Derived from Chinese Hamster Ovary Cells Reverses the Disease Phenotype in Recessive Dystrophic Epidermolysis Bullosa Mice","volume":"135","author":"Hou","year":"2015","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib132","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood-2008-06-161299","article-title":"Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells","volume":"113","author":"Tolar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.017_bib133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib134","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/14653241003587637","article-title":"Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa","volume":"12","author":"Conget","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2025.03.017_bib135","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.jid.2018.04.028","article-title":"Intradermal Injection of Bone Marrow Mesenchymal Stromal Cells Corrects Recessive Dystrophic Epidermolysis Bullosa in a Xenograft Model","volume":"138","author":"Ganier","year":"2018","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jid.2019.05.031","article-title":"Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras","volume":"140","author":"Petrova","year":"2020","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib137","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.jid.2023.05.021","article-title":"Gene-Modified Blister Fluid-Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa","volume":"143","author":"Kikuchi","year":"2023","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib138","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.017_bib139","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.mt.6300041","article-title":"Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing","volume":"15","author":"Woodley","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/sctm.17-0182","article-title":"Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model","volume":"7","author":"Liao","year":"2018","journal-title":"Stem Cell Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib141","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143606","article-title":"Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients","volume":"6","author":"Lee","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.017_bib142","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/stem.1966","article-title":"Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa","volume":"33","author":"Liao","year":"2015","journal-title":"Stem. Cells."},{"key":"10.1016\/j.ymthe.2025.03.017_bib143","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib144","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102296","article-title":"Tissue fibroblasts are versatile immune regulators: An evaluation of their impact on the aging process","volume":"97","author":"Salminen","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ymthe.2025.03.017_bib146","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/TCRM.S386923","article-title":"Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects","volume":"19","author":"Hou","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ymthe.2025.03.017_bib147","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/biom13060988","article-title":"Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development","volume":"13","author":"Li","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2025.03.017_bib148","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"Woodley","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.017_bib149","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/bjd\/ljae063","article-title":"Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial","volume":"191","author":"Woodley","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib150","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.4103\/0028-3886.246258","article-title":"Neurotoxicity of the antibiotics: A comprehensive study","volume":"66","author":"Rezaei","year":"2018","journal-title":"Neurol. India"},{"key":"10.1016\/j.ymthe.2025.03.017_bib151","article-title":"Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides","volume":"15","author":"Fu","year":"2021","journal-title":"Front. Cel. Neurosci."},{"key":"10.1016\/j.ymthe.2025.03.017_bib152","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.taap.2007.05.004","article-title":"Glomerular nephrotoxicity of aminoglycosides","volume":"223","author":"Mart\u00ednez-Salgado","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib153","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamadermatol.2023.2077","article-title":"Treatment With Ataluren for Wound Healing and Health Complications in a Patient With Junctional Epidermolysis Bullosa","volume":"159","author":"Orlowski","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib154","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41467-022-30080-6","article-title":"Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.017_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001593","article-title":"A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays","volume":"11","author":"McElroy","year":"2013","journal-title":"Plos Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib156","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67398-8","article-title":"Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa","volume":"14","author":"Jover","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.017_bib157","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/bjd.17698","article-title":"Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses","volume":"181","author":"Chac\u00f3n-Solano","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib158","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jid.2020.11.010","article-title":"Connective Tissue and Fibroblast Senescence in Skin Aging","volume":"141","author":"Wlaschek","year":"2021","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib159","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib160","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-11-2996","article-title":"Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa","volume":"72","author":"Ng","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.017_bib161","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/mt.2013.87","article-title":"Topical Application of Recombinant Type VII Collagen Incorporates Into the Dermal-Epidermal Junction and Promotes Wound Closure","volume":"21","author":"Wang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib162","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv293","article-title":"Suppression of TGF\u03b2 and Angiogenesis by Type VII Collagen in Cutaneous SCC","volume":"108","author":"Martins","year":"2016","journal-title":"J.\u00a0Natl. Cancer. Inst."},{"key":"10.1016\/j.ymthe.2025.03.017_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2021.100065","article-title":"Distinct contributions of meprins to skin regeneration after injury\u00a0\u2013 meprin \u03b1 a physiological processer of pro-collagen VII","volume":"11","author":"Kruppa","year":"2021","journal-title":"Matrix Biol. Plus"},{"key":"10.1016\/j.ymthe.2025.03.017_bib164","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00004872-199507001-00002","article-title":"Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension","volume":"13","author":"Siegl","year":"1995","journal-title":"J.\u00a0Hypertens. Suppl."},{"key":"10.1016\/j.ymthe.2025.03.017_bib165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.017_bib166","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14279","article-title":"Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa","volume":"33","author":"Inamadar","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102900","article-title":"Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1\/2 trial","volume":"77","author":"Kiritsi","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ymthe.2025.03.017_bib168","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib169","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpedsurg.2022.11.001","article-title":"Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa","volume":"58","author":"Oldakovskiy","year":"2023","journal-title":"J.\u00a0Pediatr. Surg."},{"key":"10.1016\/j.ymthe.2025.03.017_bib170","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15515","article-title":"Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series","volume":"35","author":"Pourani","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib171","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15678","article-title":"Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases","volume":"35","author":"Relvas","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.017_bib172","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022960118","article-title":"Prednisolone rescues Duchenne muscular dystrophy phenotypes in human pluripotent stem cell-derived skeletal muscle in\u00a0vitro","volume":"118","author":"Al Tanoury","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.017_bib173","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.017_bib174","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.omtm.2022.01.007","article-title":"Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression","volume":"24","author":"Wang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.017_bib175","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1681\/ASN.2017060690","article-title":"Laminin-521 Protein Therapy for Glomerular Basement Membrane and Podocyte Abnormalities in a Model of Pierson Syndrome","volume":"29","author":"Lin","year":"2018","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib176","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.matbio.2016.07.012","article-title":"Cell therapy for basement membrane-linked diseases","volume":"57\u201358","author":"Nystr\u00f6m","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib177","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.clindermatol.2010.04.004","article-title":"Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies","volume":"28","author":"Price","year":"2010","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib178","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jid.2024.04.031","article-title":"RNA Therapy for Oncogenic NRAS-Driven Nevi Induces Apoptosis","volume":"145","author":"Bryant","year":"2025","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2025.03.017_bib179","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejps.2011.04.003","article-title":"Lipid-mediated gene delivery to the skin","volume":"43","author":"Geusens","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2025.03.017_bib180","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10562","article-title":"Dual gene-activated dermal scaffolds regulate angiogenesis and wound healing by mediating the coexpression of VEGF and angiopoietin-1","volume":"8","author":"Weng","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.017_bib181","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.2147\/IJN.S490027","article-title":"Nanoparticle-Based Therapeutics for Enhanced Burn Wound Healing: A Comprehensive Review","volume":"19","author":"Shi","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2025.03.017_bib182","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s42087-021-00210-5","article-title":"Exploring the Preconditions for a Developmental Science: Hegelian Metaphysics and Dialectics","volume":"6","author":"Ebbesen","year":"2023","journal-title":"Hu. Arenas"},{"key":"10.1016\/j.ymthe.2025.03.017_bib183","article-title":"Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa","volume":"35","author":"Paller","year":"2024","journal-title":"J.\u00a0Dermatolog. Treat."},{"key":"10.1016\/j.ymthe.2025.03.017_bib184","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14737167.2023.2245138","article-title":"Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step","volume":"23","author":"Frederix","year":"2023","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.ymthe.2025.03.017_bib185","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:41:26Z","timestamp":1792687286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":185,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525001625001911"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in skin gene therapy: From the inside and out","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}